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Introduction {#sec1}
============

The mammalian mitochondrial genome encodes 13 essential protein components of the mitochondrial oxidative phosphorylation system, as well as the full complement of tRNAs and rRNAs required for the synthesis of these proteins within mitochondria. The life cycle of a mitochondrial RNA (mtRNA) molecule begins with transcription initiation from one of two promoters, the light-strand promoter (LSP) or the heavy-strand promoter (HSP) ([@bib20]). Transcription initiation minimally requires three proteins comprising a bacteriophage T7-like mtRNA polymerase (POLRMT) together with mitochondrial transcription factor A (TFAM) and transcription factor B2 (TFB2M) ([@bib16], [@bib56]). A stepwise model for mitochondrial transcription initiation has been elucidated from biochemical and structural studies in recent years. First, TFAM binds to the promoter region, imposing a sharp U-turn in the DNA and recruiting POLRMT, which becomes positioned at the transcription start site (TSS) ([@bib17], [@bib41]). TFB2M then binds to this complex and facilitates melting of the promoter DNA ([@bib21], [@bib42], [@bib49], [@bib59]), allowing POLRMT to initiate RNA synthesis.

Transcription in mitochondria is polycistronic, with mRNAs and rRNAs interspersed ("punctuated") with tRNAs ([@bib46]). Once these tRNAs have folded into their canonical cloverleaf structures in the precursor RNAs, they are recognized and cleaved at their 5′ and 3′ ends by RNase P and ELAC2, respectively ([@bib6], [@bib22], [@bib55]), which serve to excise individual transcripts.

The degradation of mtRNAs has long been poorly understood but has seen several recent advances. The most well-characterized degradation machinery in the human mitochondrial matrix is a complex of the phosphorylytic exoribonuclease PNPase with the helicase SUV3, collectively termed the RNA degradosome ([@bib4], [@bib60]). PNPase processively releases mononucleoside diphosphates as reaction products but is unable to degrade short RNA molecules of less than ∼4 nt in length ([@bib31]). The loss of mitochondrial PNPase causes the accumulation of antisense RNAs ([@bib48]) as well as double-stranded RNAs ([@bib13]), implicating a role for PNPase in the removal of these molecules, and it remains unclear which other RNases also contribute to RNA turnover.

In *E. coli*, the final stage of RNA degradation is the hydrolysis of short RNA fragments of 2--5 nt in length, termed nanoRNAs ([@bib37]). This process requires the conserved and essential oligoribonuclease Orn ([@bib18], [@bib45]). Orn is a 3′-5′ exonuclease of the DEDDh family that releases mononucleotides as reaction products ([@bib11]) and was recently found to show a strong preference for dinucleotide substrates ([@bib25]). The loss of Orn results in large-scale alterations in gene expression that have been attributed to the ability of nanoRNAs to mediate transcription priming ([@bib14], [@bib19], [@bib63]).

The human homolog of Orn is called REXO2 and is an active ribonuclease ([@bib36], [@bib43]) that localizes to the mitochondrial matrix, the intermembrane space, and the cytosol ([@bib5]). Depletion of REXO2 in human cells causes severe effects on mitochondrial DNA copy number, mitochondrial transcript levels, and mitochondrial translation ([@bib5]), but the molecular basis for these wide-ranging effects on mitochondrial gene expression are unclear.

In this work, we reassess the role of REXO2 in mitochondria. We find that REXO2 is a sugar-independent dinucleotide-degrading enzyme, as supported by *in vitro* biochemistry and crystal structures of the apo and substrate-bound enzyme forms. We find that REXO2 is an essential gene in mice and that a heart- and skeletal-muscle-specific conditional knockout model exhibits changes in both promoter-dependent and promoter-independent transcription initiation indicating dinucleotide-mediated priming of mitochondrial transcription from both canonical and non-canonical sites.

Therefore we conclude that the activity of REXO2 is essential for both RNA turnover and the maintenance of promoter specificity in mammalian mitochondria.

Results {#sec2}
=======

REXO2 Is an RNA and DNA Dinucleotidase {#sec2.1}
--------------------------------------

REXO2 degrades oligonucleotides of ∼5 nt in length, with a preference for RNA substrates ([@bib10], [@bib43]). We expressed and purified full-length human REXO2 from *E. coli* ([Figure S1](#mmc1){ref-type="supplementary-material"}A) and assessed the activity of the recombinant protein upon nanoRNA substrates *in vitro*. REXO2 exhibited a strong preference for dinucleotides relative to 3-, 4-, or 5-mer substrates, with little sequence specificity ([Figures 1](#fig1){ref-type="fig"}A and 1B). RNA 3-, 4-, or 5-mers could be fully degraded only at significantly higher enzyme concentrations ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1D). Surprisingly, when the activity of recombinant REXO2 was assessed upon DNA oligonucleotides of equivalent sequences, a comparable activity was observed as the one obtained with RNA dinucleotides ([Figures 1](#fig1){ref-type="fig"}C and 1D). However, no activity was observed upon longer DNA oligos of 3--5 nt in length at these enzyme concentrations ([Figures 1](#fig1){ref-type="fig"}C and 1D) or even at higher concentrations ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1E), demonstrating that this sugar-nonspecific activity of REXO2 is restricted to dinucleotide substrates.Figure 1Human REXO2 Is a Dinucleotidase(A) Activity of wild-type REXO2 upon RNA substrates of different lengths. Monophosphorylated radiolabeled substrate (10 fmol) was incubated with the indicated amount of REXO2 at 37°C for 30 min, separated by 18% urea-PAGE, and imaged by autoradiography.(B) Quantification of RNA degradation by REXO2 from (A).(C) Activity of wild-type REXO2 upon DNA substrates of different lengths. Monophosphorylated radiolabeled substrate (10 fmol) was incubated with the indicated amount of REXO2 at 37°C for 30 min, separated by 18% urea-PAGE, and imaged by autoradiography.(D) Quantification of DNA degradation by REXO2 from (C).

Structural Basis for REXO2 Substrate Specificity {#sec2.2}
------------------------------------------------

To gain molecular insight into the mechanism and specificity of nucleotide degradation by REXO2, we crystallized the human protein comprising residues 39--216, which retains catalytic activity ([Figures S1](#mmc1){ref-type="supplementary-material"}F--S1I), and determined its structure to 2.0 Å resolution ([Table 1](#tbl1){ref-type="table"}). As previously reported ([@bib10], [@bib25]), the protein crystallizes as a dimer and has an RNase-H-like fold that is composed of five central β strands surrounded by nine α helices on opposite sides ([Figures 2](#fig2){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}C). Each monomer harbors an active site formed by the conserved acidic DEDD residues D47, E49, D147, and D199 that are positioned for nucleotide binding ([Figure 2](#fig2){ref-type="fig"}A), and mutation of any one of the conserved DEDD residues to alanine severely impaired the catalytic activity of the enzyme ([Figures 2](#fig2){ref-type="fig"}B--2D), consistent with their key role in catalysis.Table 1Data Collection and Refinement StatisticsREXO2REXO2-D199A-pApAREXO2-D199A-dAdA**Data Collection**Wavelength (Å)0.91840.97621.2824Space groupC222~1~C222~1~C222~1~Cell dimensions*a*, *b*, *c* (Å)36.2, 128.5, 170.235.6, 125.8, 167.935.8, 126.9, 168.2α, β, γ (°)90, 90, 9090, 90, 9090, 90, 90Resolution (Å)42.6--2.0 (2.12-2.00)42.0--2.0 (2.04-1.97)42.1-2.25 (2.38-2.25)*R*~meas~ (%)10.8 (93.5)8.0 (165.8)7.7 (150.4)CC~1/2~99.7 (56.4)99.9 (69.9)99.9 (53.6)*I* /σ(*I)*8.47 (1.26)13.4 (1.1)14.2 (1.2)Completeness (%)98.8 (97.8)100.0 (100.0)99.7 (98.6)**Refinement**Resolution (Å)22.7-2.00 (2.01-2.00)41.98-1.97 (1.98-1.97)21.8-2.25 (2.33-2.25)No. reflections272742731918796*R*~*work*~*/R*~*free*~0.1978/0.23220.2029/0.25120.2121/0.2480**No. atoms**Protein266326752675Nucleic acid4442Water24719783*B*-factorsProtein48.9758.3373.27Nucleic acid57.0071.63Water51.4962.6069.90**RMSDs**Bond lengths (Å)0.0100.0100.010Bond angles (°)1.591.581.58Ramachandran plot favored/allowed (%)[a](#tblfn1){ref-type="table-fn"}99.37/0.6399.06/0.9499.38/0.62Clashscore[a](#tblfn1){ref-type="table-fn"}1.131.851.11Molprobity score[a](#tblfn1){ref-type="table-fn"}0.820.950.82[^5][^6]Figure 2Structural Basis of REXO2 Substrate Specificity(A) Front view of the overall structure of REXO2. Monomer A (gray) and monomer B (blue) are shown in cartoon representation with the DEDDh residues of monomer A shown as sticks. Stars indicate the active sites of monomer A and monomer B. Monomer B lacked clear density for regions encompassing helices α2--4 (residues 84--113) and a short loop corresponding to residues 189--192 and were therefore not built in the model.(B) Activity of truncated REXO2 variants (amino acids 39--216) upon RNA or DNA AA dinucleotide substrates. Monophosphorylated radiolabeled substrate (10 fmol) was incubated with the indicated amounts of REXO2 at 37°C for 30 min, separated by 18% urea-PAGE, and imaged by autoradiography.(C) Quantification of RNA degradation by REXO2 variants from (B).(D) Quantification of DNA degradation by REXO2 variants as in (B).(E) Surface representation of REXO2 with the RNA pApA dinucleotide (yellow) shown as sticks. The molecular surface is colored by the local electrostatic potential (blue, +5 kT; red, −5 kT).(F) Enlargement of REXO2 active site with bound RNA pApA dinucleotide as in (E).(G) The REXO2 active site. Residues interacting with the RNA pApA dinucleotide (orange) are shown as sticks and the polar bonds as yellow dashes. Zn^2+^ and Mg^2+^ are shown as pink and green spheres, respectively. Water molecules are shown as gray spheres.

In order to understand the structural basis of the observed substrate specificity, we determined the structure of REXO2 complexed with either an RNA dinucleotide (pApA) or DNA dinucleotide (dAdA) in an arrested pre-catalytic state by mutating one of the DEDDh residues, D199A ([Figures 2](#fig2){ref-type="fig"}E--2G, [S3](#mmc1){ref-type="supplementary-material"}B, and S3C; [Table 1](#tbl1){ref-type="table"}). The binding of dinucleotides produced only a few significant changes in the protein structure, mainly confined to a "trigger loop" between α9 and α10 of monomer A. This contains H194, which makes a 180° shift toward the active site to bind Zn^2+^ and the phosphate oxygen OP1 of the 3′ nucleotide. This structural arrangement is in stark contrast to the apoprotein, in which the DEDDh residue H194 faces away from the active site ([Figures 2](#fig2){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}A). On the 5′ end of the dinucleotide, S143 and S170 of monomer A and R165 of monomer B form hydrogen bonds with OP1 of the nucleotide monophosphate, creating a physical boundary of the narrow active site that impedes binding of longer substrates ([Figure 2](#fig2){ref-type="fig"}G). Indeed, a structural comparison to other DEDD exonucleases ([Figures S3](#mmc1){ref-type="supplementary-material"}D--S3F; [Table S1](#mmc1){ref-type="supplementary-material"}) confirmed that a steric clash would be imposed starting from the third nucleotide, with additional clashes from nucleotide four and beyond, providing the structural basis for the strong preference of REXO2 for dinucleotide substrates.

The REXO2 dimer forms an extensive binding interface that corresponds to 16% of the surface area of each monomer ([Figures 3](#fig3){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}G). To validate the functional importance of dimerization, we created amino acid substitutions designed to break this interface ([Figures 3](#fig3){ref-type="fig"}A, 3B, and [S3](#mmc1){ref-type="supplementary-material"}H--S3K) and found that mutations that disrupt dimerization ([Figure 3](#fig3){ref-type="fig"}C) lead to a loss of enzymatic activity ([Figure 3](#fig3){ref-type="fig"}D).Figure 3REXO2 Is an Obligate Homodimer(A) Top and front views of the surface of REXO2 with monomer A (blue) and monomer B (pink), where the interface interacting residues are highlighted in darker colors. K216 is highlighted in green, and R178, W179, and L175 are highlighted in yellow.(B) The R178-W179 binding pocket is shown in cartoon representation with R178, W179, and their interacting residues shown as sticks with the same color code as in (A).(C) Gel filtration profiles of the REXO2 dimer mutants.(D) Activity of REXO2 dimerization mutants upon RNA or DNA AA dinucleotides. Monophosphorylated radiolabeled substrate (10 fmol) was incubated with the indicated amounts of REXO2 protein at 37°C for 30 min, separated by 18% urea-PAGE, and imaged by autoradiography.

REXO2 Is Essential for Embryonic Development {#sec2.3}
--------------------------------------------

To investigate the *in vivo* importance for REXO2's ability to degrade dinucleotides, we generated a *Rexo2* conditional knockout allele (*Rexo2*^+/loxP^) using the Cre-*loxP* system. Heterozygous knockout mice (*Rexo2*^+/−^) were obtained by breeding *Rexo2*^+/loxP^ mice with transgenic mice expressing Cre recombinase (*+/β-actin-cre*) ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Intercrossing of *Rexo2*^+/−^ mice produced no viable homozygous knockout (*Rexo2*^−/−^) mice (analyzed offspring, n = 119; *Rexo2*^+/+^, n = 48; *Rexo2*^+/−^, n = 71; and *Rexo2*^−/−^, n = 0), indicating that loss of *Rexo2* results in embryonic lethality. Next, we performed an intercross of *Rexo2*^+/−^ mice and analyzed embryos at embryonic day 8.5 (E8.5; analyzed embryos, n = 13). Embryos with the *Rexo2*^+/+^ (n = 3) or *Rexo2*^+/−^ (n = 8) genotype were well developed with normal appearance ([Figure 4](#fig4){ref-type="fig"}A), while embryos with the *Rexo2*^−/−^ genotype (n = 2) were small and lacked heart structure ([Figure 4](#fig4){ref-type="fig"}B). Thus, *Rexo2* is essential for embryonic development, and loss of REXO2 causes embryonic lethality before E8.5.Figure 4REXO2 Is Essential for Embryonic Development(A and B) Morphology of *Rexo2*^*+/+*^ (A) and *Rexo2*^*−/−*^ (B) embryos at embryonic day 8.5. Scale bar, 500 μm.(C) Western blot of REXO2 levels in hearts from control (L/L) and tissue-specific *Rexo2* knockout (L/L, cre) mice. VDAC is used as a loading control.(D) mtDNA copy number in control and *Rexo2* knockout mice measured by qPCR using three TaqMan probe sets to different regions of the mitochondrial genome. mtDNA levels are normalized to the level of *Actin* and represent mean values from 3 independent experiments with total n = 15 mice for each group; error bars represent SEM.(E) Mitochondrial mRNA steady-state levels in control and *Rexo2* knockout mice analyzed by northern blotting. Data are normalized to the level of *18S rRNA* and presented as mean values from 3 independent experiments with total n = 10 mice for each group; error bars represent SEM.(F) mt-tRNA steady-state levels in control and *Rexo2* knockout mice analyzed by northern blotting. Data are normalized to the level of *5.8S rRNA* and presented as mean values from 3 independent experiments, with n = 15 mice for each group.(G) Level of the pApA RNA dinucleotide in heart tissue from control and *Rexo2* knockout mice measured using LC-MS/MS. Data represent mean values from n = 3 mice for each group; error bars represent SEM, \*\*p \< 0.01.(H) Level of the pApA RNA dinucleotide in isolated mitochondria from heart tissue of control and *Rexo2* knockout mice measured using LC-MS/MS. Data represent mean values from n = 3 mice for each group; error bars represent 1 SEM. n.p. indicates no peak.

We next disrupted *Rexo2* in heart and skeletal muscle by breeding *Rexo2*^*+/loxP*^ mice with transgenic mice expressing Cre recombinase from the muscle creatinine kinase promoter (*Ckmm-cre*). The conditional knockout *Rexo2* mice (*Rexo2*^*loxP/loxP*^*, +/Ckmm-cre*), hereafter denoted L/L, cre, were born at expected Mendelian ratios. Loss of REXO2 in heart was verified using western blotting ([Figure 4](#fig4){ref-type="fig"}C) and qPCR analyses ([Figure S4](#mmc1){ref-type="supplementary-material"}B). The loss of REXO2 in heart and skeletal muscle did not lead to any obvious phenotype, and all mice were viable and healthy at the age of 52 weeks. No differences were observed between control and *Rexo2* knockout mice in body weight ([Figure S4](#mmc1){ref-type="supplementary-material"}C), heart weight ([Figure S4](#mmc1){ref-type="supplementary-material"}D), or mtDNA copy number ([Figure 4](#fig4){ref-type="fig"}D). We used northern blotting to analyze the effects of REXO2 loss on steady-state levels of mtRNAs and found that there were no significant differences in the levels of mitochondrial rRNAs (mt-rRNAs), mitochondrial mRNAs (mt-mRNAs), and mitochondrial tRNAs (mt-tRNAs) between Rexo2 knockout mice and controls ([Figures 4](#fig4){ref-type="fig"}E, 4F, [S4](#mmc1){ref-type="supplementary-material"}E, and S4F). To determine whether mitochondrial dinucleotides are *in vivo* substrates of REXO2, we measured the abundance of the pApA RNA dinucleotide using liquid-chromatography-tandem mass spectrometry (LC-MS/MS). A marked increase in the level of RNA pApA was observed in both whole heart tissue ([Figure 4](#fig4){ref-type="fig"}G) and isolated mitochondria ([Figure 4](#fig4){ref-type="fig"}H) in the absence of REXO2, suggesting that this is a substrate of mitochondrial REXO2 *in vivo*.

Accumulation of Dinucleotides Results in Promoter-Independent Transcription Initiation {#sec2.4}
--------------------------------------------------------------------------------------

We used parallel analyses of RNA ends (PARE) to determine the distribution of 5ʹ ends across the entire mitochondrial transcriptome and reveal additional mitochondrial gene expression changes in the absence of REXO2. This method captures ∼20-nt-long tags from the 5ʹ ends of 5ʹ-monophosphorylated RNAs ([@bib54]), with the normalized read count at each 5ʹ terminal position appearing as a peak enabling the identification of 5ʹ sites from canonical, *de novo*, or degraded transcripts. We identified numerous non-canonical peaks that are enriched in the absence of REXO2 ([Figure 5](#fig5){ref-type="fig"}A, shown in red). To assess whether these changes may be attributed to alterations of ribonucleoside triphosphate (NTP) levels in the absence of REXO2, we measured nucleotide concentrations from either whole heart tissue or isolated mitochondria of wild-type and *Rexo2* knockout mice ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B), which did not reveal any significant differences. However, by analyzing the frequency of different dinucleotide sequences at the 5ʹ ends of captured sequence tags, we found that in *Rexo2* knockout mice, there was an enrichment of AA, AC, and AT dinucleotides, while all other 5ʹ dinucleotides were depleted ([Figure 5](#fig5){ref-type="fig"}B). As ATP is used as the initiating nucleotide at both promoters *in vivo* by the mtRNA polymerase, we reasoned that the accumulation of dinucleotides ([Figures 4](#fig4){ref-type="fig"}G--4H) upon loss of REXO2 may prime low levels of transcription at non-canonical sites.Figure 5Loss of REXO2 Causes nanoRNA-Primed Non-canonical Mitochondrial Transcription Initiation(A) A complete map of changes in 5ʹ-end abundance (log2 fold change \[knock out (KO)mean/control (Ctrl)mean\]) from three control (L/L) and three *Rexo2* knockout (L/L, cre) mice on heavy (top) and light (bottom) strands. Mean increases are shown in red and mean decreases in blue. A schematic of the mitochondrial genome is displayed in the center; rRNAs are displayed in green, mRNAs in blue, tRNAs in gray, and the non-coding region (NCR) in black.(B) Frequency of all possible dinucleotide combinations found at the 5ʹ ends of captured sequence tags in three control and *Rexo2* knockout mice.(C) *In vitro* transcription reactions using supercoiled pBluescript II SK (+) DNA as a template. Reactions contain 20 μM ATP, CTP, and GTP; 1 μM UTP; 0.2 μCi ^32^P α-UTP; and 20 μM of the indicated RNA or DNA oligonucleotide.(D) *In vitro* transcription reactions as in (C) but containing BamHI-linearized pBluescript II SK (+) DNA as a template. Reactions using a supercoiled template (lanes 12 and 13) are included as a positive control.

To validate this finding, we used a reconstituted human mitochondrial *in vitro* transcription system consisting of POLRMT and the two essential transcription factors, TFAM and TFB2M ([@bib16]). Transcription initiation by this complex usually requires one of the two mtDNA promoters, LSP or HSP. Accordingly, no transcription initiation is observed using a plasmid template lacking a promoter sequence ([Figure 5](#fig5){ref-type="fig"}C, lane 3). However, upon the addition of oligonucleotide(A) nanoRNAs to this reaction, we observed robust transcription initiation in the absence of a recognizable promoter ([Figure 5](#fig5){ref-type="fig"}C, lanes 4--7). Transcription initiation without a promoter was only observed using RNA primers ([Figure 5](#fig5){ref-type="fig"}C, compare lanes 4--7 with lanes 8--11) and only with closed circular templates, not with linear templates ([Figure 5](#fig5){ref-type="fig"}D). This indicates that negative supercoiling of circular DNA molecules is required for nanoRNAs to access the template in order to prime transcription. The ability of nanoRNAs to prime transcription remained evident at low concentrations relative to that of the normal initiating nucleotide ATP ([Figures S5](#mmc1){ref-type="supplementary-material"}C and S5D), indicating that nanoRNAs are potent primers of promoter-independent mitochondrial transcription. Furthermore, by using nanoRNAs of different sequences, we found that different nanoRNA sequences are capable of priming promoter nonspecific transcription providing that the 3ʹ end contains a pair of adenine residues ([Figure S5](#mmc1){ref-type="supplementary-material"}E, lanes 10--14), highlighting their potential to exert broad effects upon transcription.

nanoRNAs Stimulate Promoter-Dependent Transcription Initiation {#sec2.5}
--------------------------------------------------------------

Next, we investigated the effects of the loss of REXO2 upon promoter-dependent transcription initiation from the two mtDNA promoters, LSP and HSP. The rate of transcription initiation from both the HSP and LSP was increased in the *Rexo2* knockout mice ([Figures 6](#fig6){ref-type="fig"}A and 6B), albeit only slightly, consistent with the finding that loss of REXO2 in the heart does not cause significant pathology. It is likely that highly proliferative tissues and cells are more affected by the loss of REXO2, as the clearance of dinucleotides would be more important at increased proliferation rates. Interestingly, PARE data showed that the most enriched 5ʹ end in the LSP region is positioned at the transcription initiation site and would give rise to transcripts with 5ʹ-AG dinucleotides despite these being depleted overall in the knockout mice ([Figure 5](#fig5){ref-type="fig"}B). These findings suggest that transcription primed with AG dinucleotides is more efficient at the promoter than elsewhere in the genome.Figure 6Loss of REXO2 Causes Transcription Dysregulation at Mitochondrial Promoters(A and B) Genome browser view (log scaled) of the abundance from three control (L/L) and three *Rexo2* knockout (L/L, cre) mice (mean normalized count) and relative changes (log2 fold change\[KOmean/WTmean\]) in RNA-seq and PARE libraries showing the abundance of 5ʹ ends mapped to the HSP (A) and LSP (B). The direction of transcription from the LSP and HSP is indicated, and the cleavage site between tRNA-Phe (TF) and 12S rRNA is indicated by an upward arrow.(C) Schematic (top) shows the experimental setup of *in vitro* transcription reactions and complementarity between RNA oligonucleotides and the human LSP promoter sequence. Reactions (bottom) contain linearized or supercoiled LSP-containing plasmid template; 20 μM ATP, CTP, and GTP; 1 μM UTP; 0.2 μCi ^32^P α-UTP; and 20 μM of the indicated RNA oligonucleotide (red). Oligonucleotide sequences are designed to anneal to the promoter sequence at the transcription start site as indicated. "RO" indicates the runoff transcription product, and "PT" indicates transcription products prematurely terminated at CSB2.(D) *In vitro* transcription reactions as in (C) but containing linearized or supercoiled human HSP-containing plasmid as a template. A base in the AAAA RNA oligonucleotide (red) that is not complementary to the HSP sequence is shown in yellow in the schematic.(E) *In vitro* transcription reactions as in (C) but using poly(A) RNA (red) or DNA (black) oligonucleotides.(F) *In vitro* transcription reactions as in (D) but using poly(A) RNA (red) or DNA (black) oligonucleotides.

To test the capacity of nanoRNAs to prime promoter-dependent transcription initiation, we used a reconstituted human *in vitro* transcription system with templates containing either the human LSP or HSP sequence. nanoRNAs that anneal to the promoter at the TSS were found to potently stimulate transcription initiation from both the LSP and HSP ([Figures 6](#fig6){ref-type="fig"}C and 6D). Similar to the observation of nanoRNA-primed transcription in the absence of a promoter ([Figure S5](#mmc1){ref-type="supplementary-material"}E), the promoter-dependent effect was only observed using oligonucleotides containing AA at the 3′ end ([Figures 6](#fig6){ref-type="fig"}C and 6D). However, in contrast to results obtained with promoter-less templates, nanoRNAs are capable of priming promoter-dependent transcription using both linear templates and supercoiled templates ([Figures 6](#fig6){ref-type="fig"}C and 6D, compare lanes 3--8 with lanes 9--14). Although supercoiling was dispensable, nanoRNA-primed transcription remained absolutely dependent on the presence of TFB2M ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B, compare lanes 3--8 with lanes 9--14), which contributes critically to promoter melting ([@bib21], [@bib42], [@bib49], [@bib59]). The stimulation of transcription initiation by nanoRNAs was again observed at concentrations of nanoRNA much lower than that of ATP ([Figures S6](#mmc1){ref-type="supplementary-material"}C and S6D) and was not seen using DNA primers ([Figures S6](#mmc1){ref-type="supplementary-material"}E and S6F), indicating that nanoRNAs are used in preference to ATP to initiate transcription. Interestingly, the RNA 4-mer AAAA was able to prime transcription initiation from HSP despite not fully annealing to the promoter sequence. Primer extension analysis of nanoRNA-primed transcription products was used to determine the exact site at which this nanoRNA anneals to the promoter during transcription initiation. This revealed a mixture of different RNA 5′ ends ([Figure S7](#mmc1){ref-type="supplementary-material"}A), indicating that only the 3′ end of this nanoRNA is required to anneal in order to prime transcription, although transcript length may also be influenced by reiterative initiation at the TSS. We therefore also tested the ability of poly(A) nanoRNAs of different lengths to prime transcription from the LSP or HSP. All poly(A) sequences tested were capable of efficiently stimulating promoter-dependent transcription ([Figures 6](#fig6){ref-type="fig"}E, 6F, [S7](#mmc1){ref-type="supplementary-material"}B, and S7C). The addition of the mitochondrial transcription elongation factor TEFM into nanoRNA-primed transcription reactions reduced the rate of pre-termination by the transcription complex, as expected ([@bib23], [@bib40], [@bib50]), but did not alter the rate of transcription initiation ([Figures S7](#mmc1){ref-type="supplementary-material"}D and S7E, compare lanes 3--8 with lanes 9--14), indicating that TEFM does not contribute to transcription primed by nanoRNAs.

Loss of REXO2 Causes an mtRNA Processing Defect {#sec2.6}
-----------------------------------------------

We carried out RNA sequencing (RNA-seq) of RNA from *Rexo2* knockout mice and wild-type controls followed by differential expression analysis, which found no significant changes in the overall levels of mitochondrial transcripts and no large changes in nuclear gene expression ([Table S2](#mmc2){ref-type="supplementary-material"}). We used the RNA-seq data to investigate if the increased presence of dinucleotides as a consequence of REXO2 loss can interfere with RNA processing and thereby cause an accumulation of mtRNA precursors. RNA-seq captures longer RNAs, such as mRNAs and rRNAs, but excludes mature tRNAs, providing a way to investigate the accumulation of tRNA-containing precursor transcripts in mitochondria since they are produced from the same polycistronic transcript ([@bib54], [@bib57]). We identified increases in the levels of precursor transcripts across the tRNA junctions that span each mRNA ([Figure 7](#fig7){ref-type="fig"}A) and rRNA ([Figure 7](#fig7){ref-type="fig"}B). To show that the accumulated transcripts were not only a consequence of increased transcription in the absence of REXO2, we also investigated the PARE datasets for changes in canonical cleavage sites across the entire mitochondrial transcriptome. In the REXO2 knockout mice, we identified decreases in the levels of 5ʹ tRNA canonical sites, whereas the levels of 3ʹ tRNA cleavage sites or non-canonical sites were either increased or not affected in the absence of REXO2 ([Figure 7](#fig7){ref-type="fig"}C). This suggests that an increased abundance of dinucleotides interferes with the processing of 5ʹ ends of mt-RNAs.Figure 7Loss of REXO2 Causes an RNA Processing Defect(A and B) A complete map of mtRNA abundance and mean (log2 fold change \[KOmean/Ctrlmean\]) determined by RNA-seq coverage from control (n = 3) and *Rexo2* knockout (n = 3) mice on the heavy (upper) and light (lower) strand with the mtDNA genome positioned in the centre. Increases (red) and decreases (blue) are depicted for the coding regions (A) and rRNA regions (B).(C) Changes in the levels of canonical mtRNA junctions were determined from the PARE datasets.

Discussion {#sec3}
==========

We have established REXO2 as a specialized dinucleotide-degrading enzyme in mammalian mitochondria. REXO2 acts as the final stage in mtRNA degradation, as the mononucleotides released by REXO2 can be recycled for further rounds of transcription. The best-characterized ribonuclease involved in mtRNA degradation, PNPase, is unable to degrade substrates of less than 4 nt in length ([@bib31]) and therefore acts upstream of REXO2 in mtRNA degradation. However, it remains unclear whether these products of PNPase are further processed by other RNases or whether other enzymes also generate substrates for REXO2. The mitochondrial nuclease ExoG releases dinucleotides as reaction products and is active upon RNA ([@bib62], [@bib65]) and so could potentially fulfill this role. Interestingly, a very recent study of *E. coli* Orn has similarly revealed a stark preference for diribonucleotide substrates ([@bib25]), suggesting that oligoribonucleases have a more specialized and evolutionarily conserved role than previously understood. A second potential source of nanoRNAs in mitochondria are cycles of abortive transcription by POLRMT. Similarly to RNA polymerases in other systems, POLRMT engages in frequent rounds of abortive transcription initiation, releasing very short RNA products ([@bib8], [@bib17], [@bib34]). As these RNAs are capable of annealing to the TSS, their rapid degradation is presumably required to prevent their use as primers.

The capacity of REXO2 to also efficiently degrade DNA dinucleotides ([Figure 1](#fig1){ref-type="fig"}C) suggests that REXO2 may also be involved in the terminal stage of mtDNA breakdown. Two recent studies have implicated the 3′--5′ exonuclease (proofreading) activity of the mitochondrial DNA polymerase POLγ and the exonuclease MGME1 in mtDNA degradation ([@bib44], [@bib47]). POLγ releases mononucleotides as reaction products ([@bib27]), but MGME1 cleaves single-stranded DNA in a distributive manner to release short oligonucleotides ([@bib26], [@bib61]), which may represent good substrates for REXO2; thus, the role of REXO2 in mtDNA metabolism warrants further investigation.

The RNA substrates of REXO2 were found to be potent stimulators of mitochondrial transcription, both from canonical promoters and non-canonical sites. In bacteria, it has been suggested that the priming of transcription by nanoRNAs is a physiological mechanism to regulate the activity of certain promoters, as the rate of nanoRNA-primed transcription varies according to the growth stage of the cells ([@bib14], [@bib63]). The observation that nanoRNAs alter the rate of transcription initiation from both mitochondrial promoters ([Figure 6](#fig6){ref-type="fig"}) suggests that such a system is formally possible in mammalian mitochondria. However, the fact that the same nanoRNAs also prime transcription at non-canonical sites ([Figure 5](#fig5){ref-type="fig"}) makes such a system appear unlikely unless additional mechanisms exist to maintain promoter specificity *in vivo*. The stimulation of *in vitro* transcription initiation by nanoRNAs ([Figure 6](#fig6){ref-type="fig"}) suggests that the formation of the first phosphodiester bond by POLRMT represents a rate-limiting step for transcription initiation. This observation is in agreement with previous studies showing that the yeast mtRNA polymerase requires high ATP concentrations for the formation of the first phosphodiester bond, but not for elongation ([@bib2], [@bib3]). This ATP sensing mechanism could potentially couple transcription levels to respiration. For this model to function, AA dinucleotides, in which the first phosphodiester bond has already been formed, must be eliminated so that they do not serve as primers for transcription. REXO2 may serve this purpose.

The use of ATP as an initiating nucleotide leads to primary transcripts carrying a triphosphate at the 5′ end. In *E. coli*, this triphosphate acts to stabilize transcripts, while decapping of the RNA leads to the degradation of the resulting monophosphorylated transcript by RNase E ([@bib12]). The possibility of a similar mechanism operating in mammalian mitochondria is precluded by the fact that the processing of polycistronic mtRNA precursors leads to the mature transcripts bearing a 5′ monophosphate ([@bib46]) and means that other mechanisms must be required to mark mitochondrial transcripts for degradation. Selective degradation of antisense mtRNAs has recently been suggested to be mediated by GRSF1 in conjunction with the degradosome ([@bib48]), but there is currently no known mechanism to distinguish between full-length and truncated sense-strand transcripts. This would presumably make it difficult to distinguish between mature transcripts and those initiated from non-canonical sites in mitochondria and helps to explain why transient depletion of REXO2 causes severe effects upon mitochondrial gene expression ([@bib5]).

The importance of a dinucleotidase activity is highlighted by the fact that REXO2 is essential for embryonic development ([Figure 4](#fig4){ref-type="fig"}). The finding that a heart-specific knockout of REXO2 was viable was therefore surprising but presumably reflects a greater requirement for this activity in proliferative tissues during development. The knockout of REXO2 results in embryonic lethality at around E8.5, similar to other genes involved in mtDNA maintenance and expression ([@bib9], [@bib29], [@bib39]). The role of the cytosolic form of REXO2 therefore appears less critical but would represent an interesting topic for future study.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Rabbit polyclonal anti-REXO2AbcamCat\# ab206694Anti-VDACAbcamCat\# ab14734; RRID:[AB_443084](nif-antibody:AB_443084){#intref0010}**Bacterial and Virus Strains**Rosetta 2 Competent CellsMerck MilliporeCat\#71402Single Step (KRX) Competent CellsPromegaCat\#L3002*Autographa californica* nuclear polyhedrosis virusClontechCat\#631401**Chemicals, Peptides, and Recombinant Proteins**Human REXO2-6His WTThis paperN/AHuman REXO2 39-216, WT and point mutantsThis paperN/AHuman POLRMT[@bib16]N/AHuman TFAM[@bib16]N/AHuman TFB2M[@bib16]N/AHuman TEFM[@bib50]N/A**Critical Commercial Assays**HIS-Select Nickel Affinity GelSigma-AldrichCat\#P6611HiLoad 16/600 Superdex 200 pg Gel Filtration ColumnsGE HealthcareCat\#28989335HiTrap Q HPGE HealthcareCat\#29051325Superdex 75 Increase Size Exclusion ColumnsGE HealthcareCat\#29148721Amersham ECL Western Blotting Detection ReagentGE HealthcareCat\# RPN2106High molecular weight native maker kitGE HealthcareCat\# 17-0445-01Trizol reagentThermo FisherCat\# 15596026High-Capacity cDNA Reverse Transcription KitThermo FisherCat\#4368814TaqMan Universal Mast er Mix II, with UNGThermo FisherCat\#4440038T4 Polynucleotide KinaseNew England BiolabsCat\# M0201RNase A, DNase and protease-freeThermo FisherCat\# EN0531DNeasy Blood and Tissue KitQIAGENCat\# 69506Ribo-Zero rRNA Removal KitIlluminaCat\#MRZH116Superscript II Reverse Transcriptase KitThermo FisherCat\#19064014miRNeasy Mini KitQIAGENCat\# 217004TURBO DNA-free KitThermo FisherCat\# AM1907Platinum SYBR Green qPCR supermix-UDGThermo FisherCat\# 11733046Prime-It II Random Primer Labeling KitAgilentCat\# 300385**Deposited Data**REXO2 (apo) structureThis paperPDB: [6RCI](pdb:6RCI){#intref0015}REXO2 (pApA-bound) structureThis paperPDB: [6RCL](pdb:6RCL){#intref0020}REXO2 (dAdA-bound) structureThis paperPDB: [6RCN](pdb:6RCN){#intref0025}RNA-seq and PARE dataThis paperGEO: [GSE129707](ncbi-geo:GSE129707){#intref0030}Original image dataThis paper<https://doi.org/10.17632/ss68bdtccy.1>**Experimental Models: Cell Lines***Spodoptera frugiperda*: Sf9 CellsClontechCat\#631402**Experimental Models: Organisms/Strains**Mouse: C57BL/6N *Rexo2*^+/−^This paperN/AMouse: C57BL/6N *Rexo2*^*loxP/loxP*^*, +/Ckmm-cre*This paperN/A**Oligonucleotides**2-5-mer RNA and DNA oligos, see [Table S3](#mmc1){ref-type="supplementary-material"}This paperN/APrimer for qPCR, see [Table S3](#mmc1){ref-type="supplementary-material"}This paperN/APrimers for Northern blot probes, see [Table S3](#mmc1){ref-type="supplementary-material"}This paperN/ApApA, standard for mass spectrometryBiologCat\#P033hLSP_PEx primer, see [Table S3](#mmc1){ref-type="supplementary-material"}This paperN/A**Recombinant DNA**Plasmid: pETM-11-REXO2This paperN/APlasmid: pBluescript II SK(+)StratageneCat\#212205Plasmid: pUC18 m.1-477[@bib16]N/APlasmid: pUC18 m.499-742[@bib16]N/A**Software and Algorithms**XDSMPI for Medical Research, Heidelberg<http://xds.mpimf-heidelberg.mpg.de/>PhaserCambridge Institute for Medical Research<https://www.phaser.cimr.cam.ac.ukindex.php/Phaser_Crystallographic_Software>AutobuildPHENIX Online<https://www.phenix-online.org/documentation/reference/autobuild.html>COOTMRC LMB<https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/>BusterGlobal Phasing<https://www.globalphasing.com/buster/>MolProbityDuke University<http://molprobity.biochem.duke.edu/>PymolSchrödinger<https://pymol.org/2/>Bowtie 2Johns Hopkins University<http://bowtie-bio.sourceforge.net/bowtie2/index.shtml>BedtoolsUniversity of Utah<https://bedtools.readthedocs.io/en/latest/>featureCountsWalter and Eliza Hall Institute<http://bioinf.wehi.edu.au/featureCounts/>DESeq 2Bioconductor<https://bioconductor.org/packages/release/bioc/html/DESeq2.html>CLC Genomics WorkbenchQIAGEN<https://www.qiagenbioinformatics.com/products/clc-genomics-workbench/>RThe R Project for Statistical Computing<https://www.r-project.org/>MultiGauge V3.0FujifilmN/AGraphPad PrismGraphPad Software<https://www.graphpad.com/scientific-software/prism/>ImageQuant TL 8.1GE Healthcare<http://www.gelifesciences.com/en/us/shop/protein-analysis/molecular-imaging-for-proteins/imaging-software/imagequant-tl-8-1-p-00110>

Lead Contact and Materials Availability {#sec4.2}
---------------------------------------

Requests for reagents and resources should be directed to, and will be fulfilled by, the lead contact, Claes Gustafsson (<claes.gustafsson@medkem.gu.se>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Mice {#sec4.3.1}

All mice in this study had an inbred C57BL/6N background. Animal studies were approved by the animal welfare ethics committee and performed in compliance with National and European law.

Method Details {#sec4.4}
--------------

### Cloning and Purification of REXO2 {#sec4.4.1}

Codon-optimized (Genscript) DNA constructs corresponding to amino acids 39-216 of human REXO2 was cloned in a pETM-11 vector (EMBL). REXO2 was expressed in Rosetta 2 cells (EMD chemicals) by autoinduction in Magic media (Invitrogen) at 25°C for 16 hours. After lysis, the proteins were purified over a His-Select Ni^2+^ (Sigma-Aldrich) resin and dialyzed against H-0.2 (25 mM Tris-HCl \[pH 7.8\], 0.5 mM EDTA, 10% glycerol, 1 mM DTT, 0.2 M NaCl) after the addition of TEV protease at a 1:10 protease:protein ratio. Further purification was conducted over a HiLoad 16/60 Superdex 200 pg gel filtration column (GE Healthcare) in buffer H-0.2 lacking glycerol and concentrated using Vivaspin concentrators (10,000 Da MWCO, Sartorius). Dimerization mutants were dialyzed against H-0.1 after the Ni^2+^ purification step and further purified over a Hitrap-Q (1 ml) column equilibrated in H-0.1. After washing with H-0.1 the proteins were eluted with a 30 mL linear gradient between H-0.1 and H-1.0. The dimerization state was determined on a Superdex 75 increase (GE Healthcare) column equilibrated in H-0.5 lacking glycerol.

### Nuclease Assays {#sec4.4.2}

REXO2 nuclease assays were performed according to the method of [@bib43]. RNA and DNA substrates were 5′ end labeled using T4 polynucleotide kinase (NEB) according to the manufacturer's instructions and purified using MicroSpin G-25 columns (GE Healthcare). Nuclease reactions (10 μl) contained 10 fmol of labeled substrate, 50 mM HEPES-KOH pH 7.4, 50 mM KCl, 10 mM MnCl2, 0.01% Triton X-100, 10% glycerol, 0.1 mM DTT and the indicated amount of REXO2 protein prepared in dilution buffer (200 mM NaCl, 100 μg/ml BSA, 0.5 mM EDTA, 20 mM Tris-Cl pH 8, 1 mM DTT, 10% glycerol). Reactions were incubated at 37°C for 30 min then stopped by the addition of 10 μl loading buffer (98% formamide, 10 mM EDTA, 0.025% xylene cyanol and 0.025% bromophenol blue) and separated by 18% denaturing PAGE. Gels were exposed to storage phosphor screens and scanned using a Fujifilm FLA-7000 for quantification, or exposed to X-ray film.

### Crystallization and Structure Determination {#sec4.4.3}

Crystals of REXO2 were grown at 23°C by the hanging drop vapor diffusion method by mixing 1 μL protein (20 mg/ml) with an equal volume of reservoir solution (100 mM HEPES pH 7.0, 200 mM sodium malonate, and 20% polyethylene glycol 3350). For soaking experiments, REXO2 D199A mutant crystals were incubated in a fresh drop containing 100 mM MES pH 5.5, 200 mM sodium malonate, 20% polyethylene glycol 3350, 20 mM MgCl~2~, 1 mM ZnCl~2~, 12% glycerol and 1 mM oligonucleotide for 30-60 min. Diffraction data were collected at beamlines 14-1 (Bessy, Berlin, Germany) and ID29 (ESRF, Grenoble, France). The data ([Table 1](#tbl1){ref-type="table"}) were processed with XDS ([@bib24]) and the structure was solved by molecular replacement with Phaser ([@bib35]), using ORN from *Escherichia coli* (PDB: [1YTA](pdb:1YTA){#intref0120}) as search model. The molecular replacement solution was used as a starting model for building by Autobuild ([@bib1]) that was further improved by manual building in COOT ([@bib15]) interspersed with refinement in Buster ([@bib58]), which rendered a final model ([Table 1](#tbl1){ref-type="table"}) that had no Ramachandran outliers as assessed by MolProbity ([@bib33]). A dataset collected near the peak of anomalous scattering by zinc (1.28 Å) was collected for the DNA bound REXO2. Both dinucleotide bound structures were solved by molecular replacement using the apo structure as the search model. Figures were prepared with Pymol (Schrödinger).

### Generation of Rexo2 Conditional Knockout Mice {#sec4.4.4}

The *Rexo2* conditional knockout mice were generated by Taconic Artemis. Exons 3-5 of the *Rexo2* locus were flanked by *loxP* sites, and two positive selection markers including a neomycin resistance cassette (NeoR) flanked by *Frt* sites and a puromycin resistance cassette (PuroR) flanked by *F3* sites were introduced in intron 2 and intron 5, respectively. The NeoR and PuroR were removed by the mating of *Rexo2*^+/loxP-Neo-Puro^ mice with transgenic mice ubiquitously expressing *Flp*-recombinase. After the *Flp* recombination, the resulting *Rexo2*^+/loxP^ mice were subsequently crossed with transgenic mice ubiquitously expressing cre-recombinase under the control of (1) the *β -actin* promoter (*+/β -actin*) to generate *Rexo2* heterozygous knockout mice (*Rexo2*^*+/−*^) or (2) the muscle creatinine kinase promoter (*+/Ckmm-cre*) to generate heart and skeletal muscle *Rexo2* conditional knockout mice (*Rexo2*^*loxP/loxP*^, *+/Ckmm-cre*; L/L, cre).

### Crude Mitochondrial Isolation {#sec4.4.5}

Mitochondria from mouse heart were isolated by differential centrifugation using isolation buffer (320 mM sucrose, 10 mM Tris-HCl, pH 7.4 and 1 mM EDTA), supplemented with protease inhibitor (Roche). Hearts were homogenized using a Potter-Elvehjem homogenizer on ice (15 strokes, 500 rpm). Nuclei and cell debris were pelleted at 1,000 g for 10 minutes at 4°C. The supernatant was centrifuged at 10,000 g for 10 min at 4°C. The differential centrifugation was repeated twice to obtain the crude mitochondria.

### Western Blot Analysis {#sec4.4.6}

Crude mitochondria or total protein (10-30 μg) were resuspended in 1 x NuPAGE LDS Sample Buffer. Mitochondrial proteins were separated by SDS-PAGE (4%--12% Bis-Tris Protein Gels; Invitrogen) and transferred onto Polyvinylidene difluoride (PVDF) membranes (Merck Millipore). Immunoblotting was performed using standard procedures and developed using ECL Reagent.

### RNA Extraction, Quantitative PCR and Northern Blot Analysis {#sec4.4.7}

RNA was extracted from heart using Trizol reagent (Thermo Fisher Scientific) according to the manufacturer's instructions, then treated with TURBO DNA-free DNase (Thermo Fisher Scientific). For qPCR expression analysis, cDNA was reversed transcribed from 1 μg total RNA using High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific). Quantitative PCR was performed in a QuantStudio 6 Flex Real-Time PCR System (Life Technologies), using (1) TaqMan Universal Master Mix II, with UNG to quantify mitochondrial transcripts (mt-rRNAs and mt-mRNAs) and *Actin*, and (2) Platinum SYBR Green qPCR supermix-UDG (Invitrogen) to quantify the levels of *Rexo2* and *Actin*. Primer sequences are shown in Table S3.

For northern blotting, 5 μg of total RNA was separated in either 1% MOPS-formaldehyde agarose gels to detect mt-mRNAs and mt-rRNAs or neutral 10% polyacrylamide gels to detect mt-tRNAs. Separated RNAs were then transferred to Hybond-N+ membranes (GE Healthcare) and hybridized with (1) randomly \[^32^P\] dCTP-labeled dsDNA probes, following the Prime-It II Random Primer Labeling Kit (Agilent), to detect mt-mRNAs (except *Nd6*), mt-rRNAs, *18S rRNA* and *5.8S rRNA*; (2) strand-specific oligonucleotide probes labeled with \[^32^P\] dATP, using T4 Polynucleotide Kinase (New England Biolabs), to detect mt-tRNAs. Radioactive signals were captured in a phosphorImager screen and was quantified using a Typhoon 7000 FLA and the ImageQuant TL 8.1 software (GE Healthcare).

### DNA Isolation, Quantification of mtDNA {#sec4.4.8}

Genomic DNA from mouse heart was isolated with the DNeasy Blood and Tissue Kit (QIAGEN) following manufacturer's instructions, followed by treatment with RNase A. Mitochondrial DNA copy number was measured by quantitative PCR using 5 ng of DNA in a QuantStudio 6 Flex Real-Time PCR System using TaqMan Universal Master Mix II. The TaqMan assays were used for the detection of mtDNA were *Nd1*, *Cox1* and *Cyb*. *18S* was used to normalize for nuclear input.

### Measurement of Dinucleotide Concentrations {#sec4.4.9}

Quantification of the linear dinucleotide pApA was performed by HPLC-coupled tandem mass spectrometry (LC-MS/MS), based on our standard method ([@bib7]). Crude mitochondria were suspended in 1200 μl ice-cold extraction solution (acetonitrile/methanol/water, 2:2:1 v/v/v, HPLC grade), or 75 mg heart tissue was mixed with 600 μl ice-cold extraction solution. Heart tissue was homogenized using a FastPrep FP120 (Thermo Savant) at 4.5 m/s for 40 s. Extracted suspensions were transferred to a new tube, and the tube used for homogenization was washed with 2 × 300 μl extraction solution and combined with the homogenate. Samples were extracted by incubation at 95°C for 10 minutes, then stored at −20°C overnight to enforce protein precipitation. Precipitated protein was pelleted by centrifugation at 20,800 g for 10 minutes at 4°C, and the supernatant dried using a SpeedVac. The dried extracts were dissolved in 150 μl H~2~O and HPLC separation was conducted by a Shimadzu LC-10 series chromatograph equipped with an EC 50/3 Nucleodur C18 Pyramid column (Macherey & Nagel), additionally coupled with a C18 security guard (Phenomenex) and a 0.5 μm column saver (Supelco). For separation of pApA, gradient elution at 30°C was used (solvent A, 10 mM ammonium acetate/0.1% acetic acid; solvent B, methanol; 0 to 4 min, 100% A; 4 to 7.3 min, 90% A; 7.3 to 8.3 min, 90% A; 8.3 to 11 min, 70% A; 11 to 11.1 min, 100% A, 11.1 to 13 min, 100%A). Retention time of pApA was 6.6 min. MS/MS analysis was carried out by an API4000 mass spectrometer (Sciex) operating in positive electrospray and multiple reaction monitoring mode. As main mass transitions \[M+H\]+ for pApA m/z 676.9 to 136.0 (quantifier) and 676.9 to 119.1 (identifier) were recorded. Quantification was done in comparison to authentic pApA (Biolog) and tenofovir as internal standard. For quantification of dinucleotide levels, precipitated cell pellets were dissolved in 800 μl of 0.1 N NaOH and heated to 95°C for 15 minutes. Protein concentrations were determined using a BCA assay.

### Measurement of Nucleotide Concentrations {#sec4.4.10}

Nucleotides from freshly dissected heart tissues and from isolated mitochondria were extracted by homogenization in 250 μl of ice-cold 12% TCA-15 mM MgCl2 solution followed by two rounds of neutralization steps using Freon-Trioctylamine mix. For determining the NTP levels, 50 μl of heart tissue samples or 150 μl of mitochondrial samples were analyzed by HPLC as described in [@bib64]. NTP levels were normalized to the total protein content in each sample, determined using a BCA assay.

### RNA Sequencing and Analyses {#sec4.4.11}

Total RNA was isolated from three control and three *Rexo2* knockout mouse hearts using a miRNeasy Mini Kit (QIAGEN), incorporating an on-column RNase-free DNase digestion, according to manufacturer's instructions. RNA quantity, purity and integrity were verified using a Bioanalyzer. RNA sequencing was performed by the Cologne Genomics Centre (Cologne, Germany) on the Illumina HiSeq platform, according to the Illumina Tru-Seq protocol, using random hexamer primers for cDNA library generation and cytoplasmic rRNA depletion using the Ribo-Zero rRNA removal kit. Sequenced reads were aligned to the mouse genome reference sequence (mm10), masked for NUMTs regions, with bowtie2 v2.3.4.1 ([@bib28]), with the--very-sensitive preset. Properly paired mitochondrial alignments were extracted, split by template strand and converted to full-length RNA fragment BED files, before coverage was calculated with BEDtools ([@bib51]) genomecov (-d -scale \[1e+06/total mapped reads\]), normalized to the total number of fragments mapped to the mouse whole genome (reads per million; RPM), and converted to wig format for visualization. Gene-level counts for the nuclear genome were calculated with featureCounts ([@bib30]) (-C --p --B --P -s 2) using the GENCODE vM20 annotation and a GENCODE-based mitochondrial annotation with contiguous *mt-Atp8/6* and *mt-Nd4l/4* intervals, and an approximate 7S RNA annotation (chrM:16035-16188). Count tables were collated in R v3.5.2 ([@bib52]) and differential expression between conditions was analyzed with DESeq2 v1.22.2 ([@bib32]).

### PARE and Analysis {#sec4.4.12}

PARE library preparation and sequencing was performed on RNA isolated from heart mitochondria from three control and three *Rexo2* knockout mouse hearts using a miRNeasy Mini Kit, as previously described ([@bib38], [@bib53]) and sequencing was performed by Vertis Biotechnologie (Freising, Germany). The 5-bp adaptor sequence was trimmed and paired-end reads were merged with CLC Genomics Workbench (QIAGEN) if the read overlap exceeded 95% identity. Merged reads were aligned to the mouse genome (mm10) with Bowtie2, using the--very-sensitive preset parameters with a shortened seed length of 10 nt ([@bib28]), and strand-specific read coverage at the 5ʹ terminal position of aligned reads was calculated with BEDtools ([@bib51]) genomecov (-d -scale \[1e+06/total mapped reads\]), normalized to the total number of fragments mapped to the mouse whole genome (reads per million; RPM), and converted to wig format for visualization. Relative changes were calculated as log~2~ fold changes of the mean normalized 5′ end coverage for three control (L/L) or knockout (L/L, cre) mice, plus a pseudocount of one. The genomic positions of the 5′ terminal nucleotides of all mapped reads were extracted using samtools, bedtools and awk. The corresponding strand-specific genomic sequences were extracted from the reference sequence and counted using bedtools and bash functions, and normalized to library size.

### Purification of Proteins for *in vitro* Transcription {#sec4.4.13}

His-tagged human POLRMT, TFAM and TFB2M were expressed individually in *Spodoptera frugiperda* (Sf9) suspension cells infected with *Autographa californica* nuclear polyhedrosis virus stocks that were prepared using the BacPAK system (Clontech) according to manufacturer's instructions. Cells were collected 60-72 hours after infection and freeze-thawed in liquid nitrogen into a lysis buffer consisting of 20 mM Tris-HCl pH 8.0, 500 mM NaCl, 10 mM β-mercaptoethanol and 1 × proteinase inhibitors (1 mM PMSF, 2 mM pepstatin A, 0.6 mM leupeptin and 2 mM benzamidine in 100% ethanol). Proteins were purified by nickel and heparin affinity chromatography according to the method of [@bib16]. His-tagged human TEFM (residues 36-360) was expressed in KRX cells (Promega) and purified using sequential nickel affinity, heparin and gel filtration columns according to the method of [@bib50].

### *In vitro* Transcription Reactions {#sec4.4.14}

Templates lacking a promoter sequence for *in vitro* transcription reactions consisted of pBluescript II SK(+), in either supercoiled form or linearized using BamHI and purified using a gel extraction kit (QIAGEN). Promoter-containing templates consisted of pUC18 containing the human mtDNA sequence region m. 1-477 (for LSP templates) or m. 499-742 (for HSP templates), inserted between BamHI and HindIII restriction sites. Where indicated, templates were linearized using BamHI (for LSP templates) or HindIII (for HSP templates) and purified using a PCR purification kit (QIAGEN). Standard *in vitro* transcription reactions (25 μl) consisted of 90 fmol DNA template, 500 fmol POLRMT, 500 fmol TFB2M, 5 pmol TFAM, 10 mM Tris-HCl (pH 8.0), 10 mM MgCl~2~, 64 mM NaCl, 100 μg/ml BSA, 1 mM DTT, 4 U murine RNase inhibitor, 10 μM UTP, 0.02 μM \[α-^32^P\] UTP (3000 Ci/mmol), and ATP, CTP and GTP as indicated in figure legends (either 20 μM each or 100 μM each). 1 pmol TEFM was also included where indicated. Reactions were allowed to proceed at 32°C for 30 minutes, before being stopped by the addition of 200 μl stop buffer (10 mM Tris-HCl (pH 8.0), 200 mM NaCl, 1 mM EDTA, 150 μg/ml proteinase K and 0.1 mg/ml glycogen). Reactions were incubated for a further 45 minutes at 42°C before being ethanol precipitated and resuspended in 10 μl loading buffer (98% formamide, 10 mM EDTA, 0.025% xylene cyanol and 0.025% bromophenol blue). Reactions were separated by 4% denaturing TBE-PAGE and imaged by autoradiography.

### Primer Extension {#sec4.4.15}

*In vitro* transcription reactions were carried out as above, except that radiolabelled UTP was omitted and all NTPs were present at a final concentration of 100 μM. Following precipitation, transcription products were resuspended in 10 μl H~2~O. This product (5 μl) was incubated with 1 pmol of end-labeled hLSP_PEx primer (labeled using T4 PNK according to manufacturer's instructions) at 65°C for 5 minutes then chilled on ice. Reverse transcription primer extension was carried out in first-strand buffer (50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl~2~) with the addition of 10 mM DTT, 1 U RNase inhibitor, 0.5 mM each dNTP and 50 U SuperScript II (Thermo Scientific) at 42°C for 50 minutes, followed by inactivation at 70°C for 15 minutes. An equal volume of loading buffer was added and products were separated by 10% urea-PAGE on sequencing gels, and imaged by autoradiography.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Nuclease assays were quantified using MultiGauge V3.0 (Fujifilm) using images generated from a Fujifilm FLA-7000. Experiments using mouse samples were performed at least three times and results are representative of n \> 5 independent biological replicates, unless indicated otherwise. All values are expressed as means ± SEM. Statistical significance between two groups was assessed by two-tailed unpaired Student's t test. Differences were considered statistically significant at a value of p \< 0.05.

Data and Code Availability {#sec4.6}
--------------------------

Crystallography datasets are available at the RCSB Protein Data Bank with accession numbers PDB: [6RCI](pdb:6RCI){#interref145} (REXO2), PDB: [6RCL](pdb:6RCL){#interref150} (REXO2-pApA) and PDB: [6RCN](pdb:6RCN){#interref155} (REXO2-dAdA).

The Gene Expression Omnibus (GEO) accession number for the data reported in this paper is GEO: [GSE129707](ncbi-geo:GSE129707){#intref0125}.

Original imaging data have been deposited in Mendeley Data and are available at <https://doi.org/10.17632/ss68bdtccy.1>
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